Please note…

You are now on the ey.com Canada site. To return to the ey.com United States site or other country site, click on the Canada (English) link on the upper right of this page, and select your preferred country site.

x
Skip to main navigation

Ernst & Young Global Biotechnology Center - Ernst & Young - Canada

  • Share

Commitment and experience for changing times

More than any other technology, More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world. But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges. Ernst & Young has been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry. We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals. So it’s not surprising that we serve more biotech companies than any other professional services firm.

Through the Ernst & Young’s Global Life Science Center, we bring together a worldwide team of industry professionals to help you achieve your potential — a team with deep experience in providing assurance, tax, transaction and advisory services specific to biotechnology companies around the globe. It’s a team that works to anticipate market trends and their implications, so you get practical advice on the right way forward for your organization.

Whether it’s raising capital, forming the right alliances, improving operations, expanding globally or gaining insights into the market, we can give you a clear perspective on how to drive value in today’s complex, competitive and risk-driven environment.

Canadian biotech losing ground — and capital — fast

With Canadian biotech companies capturing just two percent of all global capital raised in 2010, it’s clear the industry is losing ground on the global stage. Beyond borders, our annual global biotech industry report, identifies four complementary approaches for biotech companies to sustain innovation in this increasingly challenging environment.

Woman looking through window in office

Contacts

Paul Karamanoukian 
Canadian Leader
Life Sciences
514 874 4307

Beyond borders: global biotechnology report 2011 How sustainable is today’s biotechnology industry?
After slowly recovering from the recession, bigger companies are proving more successful than smaller ones. Will this trend continue and what changes are ahead for biotech. Learn more in our 25th anniversary edition of Beyond Borders. 

Back to top